Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study

BACKGROUND: Famitinib is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor receptor 2/3, platelet-derived growth factor receptor, and stem cell factor receptor (c-kit). Previous studies have demonstrated anti-tumour activities of famitinib against a w...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Qiuyan, Tang, Linquan, Liu, Na, Han, Feng, Guo, Ling, Guo, Shanshan, Wang, Jianwei, Liu, Huai, Ye, Yanfang, Zhang, Lu, Liu, Liting, Wang, Pan, Li, Yingqin, He, Qingmei, Yang, Xiaoqun, Tang, Qingnan, Li, Yang, Liang, YuJing, Sun, XueSong, Xie, Chuanmiao, Mo, Yunxian, Guo, Ying, Sun, Rui, Mo, Haoyuan, Cao, Kajia, Guo, Xiang, Zeng, Musheng, Mai, Haiqiang, Ma, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235389/
https://www.ncbi.nlm.nih.gov/pubmed/30382933
http://dx.doi.org/10.1186/s40880-018-0330-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235389/
https://www.ncbi.nlm.nih.gov/pubmed/30382933
http://dx.doi.org/10.1186/s40880-018-0330-z

Ejemplares similares